This study aimed to further our understanding of the role that hypermethylatioted in cancer 1 (HIC1) plays in prostate cancer (PCa) progression. Our data showed that HIC1 promoter hypermethylation was presented in cell lines, tissues and plasma of PCa patients. In vitro assays, restoring HIC1 expression in PCa cells by lentivirus vector or 5-Aza-2'-deoxycytidine (Decitabine) treatment markedly inhibited proliferation, migration, and invasion and induced the apoptosis in these cells. Moreover, In vivo assays showed that the mice bearing PCa-restoring HIC1 cells had a marked effect on reducing tumor growth，multiple tissue metastases and bone destruction. These findings suggest that therapies targeting epigenetic events regulating HIC1 expression may provide a more effective strategy for PCa treatment. Prostate cancer (PCa) is the second leading cause of cancer deaths among men in Western counties, which has been also occurred in Chinese male with markedly increasing incidence in recent years. Although the mechanism underlying its progression still remains unclear, epigenetic modifications are important ethological parameters. The purpose of this study is to determine the methylation status and function of hypermethylatioted in cancer 1 (HIC1) in PCa progression.
Statement of Translational Relevance
This study aimed to further our understanding of the role that hypermethylatioted in cancer 1 (HIC1) plays in prostate cancer (PCa) progression. Our data showed that HIC1 promoter hypermethylation was presented in cell lines, tissues and plasma of PCa patients. In vitro assays, restoring HIC1 expression in PCa cells by lentivirus vector or 5-Aza-2'-deoxycytidine (Decitabine) treatment markedly inhibited proliferation, migration, and invasion and induced the apoptosis in these cells. Moreover, In vivo assays showed that the mice bearing PCa-restoring HIC1 cells had a marked effect on reducing tumor growth，multiple tissue metastases and bone destruction. These findings suggest that therapies targeting epigenetic events regulating HIC1 expression may provide a more effective strategy for PCa treatment.
Introduction
Prostate cancer (PCa) is a common neoplasm and is responsible for 240,890
American men diagnosed with this disease and 33,720 deaths in 2011 (1) . In China, although accurate epidemiologic data of the whole country was not available, PCa incidence rates in developed areas (such as Shanghai, Beijing, Guangzhou etc.) have been increasing dramatically during recent ten years due in part to the wide use of screening test and adaptation of a western style diet (2) . Identifying new biomarkers repsonsible for PCa progression may prove beneficial to prevent progression and metastasis and to provide an effective therapeutic strategy for this disease.
HIC1 was originally isolated as a new candidate tumor suppressor gene because it is hypermethylated in CpG islands in many types of human cancers (3) (4) (5) (6) (7) . Many studies have observed HIC1 and p53 function by a regulatory feedback loop in which HIC1 directly represses the transcription of SIRT1 which deacetylates and thereby inactivates p53 (8, 9) . Therefore, inactivation of one allele of HIC1 results in the de-repression of SIRT1 causing decreased p53 mediated transactivation of the remaining HIC1 allele.
These findings suggest that HIC1-SIRT1-p53 regulatory loop is an essential pathway through which HIC1 may function as a tumor suppressor gene and cooperate with p53, as shown by the double heterozygote model (10). To date, given many potential physiological roles of HIC1, the number of HIC1-characterized target genes appears to be a small amount.
Although homozygous disruption of HIC1 impairs development and leads to embryonic and perinatal lethality (11), mice with heterozygous HIC1 inactivation (Hic1 +/-) have the propensity to form spontaneous tumors (12) . The presence of HIC1 silence is associated with pre-neoplastic conditions such as smoker's lung, colonic polyps and cirrhotic liver (13) . It has been reported that HIC1 is not mutated in cancers but epigenetically mediated loss of function may help drive key stages of human cancer tumorigenesis and progression. Increasing evidence suggests that HIC1 promoter was hypermethylated, including in breast (5, 14) , brain (15) , gastric (6) , liver (7) , and colorectal (16) tumors. In addition, a possible role for HIC1 in leukaemogenesis is suggested by the fact that the distal arm of chromosome 17p is often altered in advanced stages of chronic myeloid leukaemia (CML) (17) . Finally, the D17S5 microsatellite marker which allowed the positional cloning of HIC1 (3, 4) has been shown to be methylated in PCa (4) . However, the status and role of HIC1 by epigenetic modification in PCa has never been analyzed in details and thus still remains unsettled. 6 Here, we found that HIC1 promoter was hypermethylated in PCa. 
Materials and Methods
Some reagents, antibodies, and plasmids are listed in supplementary methods.
Cell cultures
The LNCaP, its metastatic subline C4-2B, and PC3 were obtained from the American Type Culture Collection (ATCC, Rockville, MD) and cultured in RPMI Medium 1640 supplemented with 10% fetal bovine serum (FBS) (Invitrogen Corp, Carlsbad, CA).
The human prostate epithelial cell line (PrEC) (PriCells Co., LTD, Wuhan, China) was cultured in keratinocyte medium supplemented with 5 ng/ml human recombinant epithelial growth factor and 50 µg/ml bovine pituitary extract (Invitrogen Corp, Carlsbad, CA).
Tissues and plasma of PCa patients
PCa tissues and the respective peripheral blood were collected from patients and healthy controls at Shanghai Ruijin Hospital, Shanghai Jiao Tong University, and Shanghai the Tenth People's Hospital of Tong Ji University after the subjects' informed consent and with institutional review board approval of the hospitals. All patients obtained a confirmed diagnosis of PCa after resection.
Construction of lentiviral vectors
For restoring expression of HIC1 in PC3 and C4-2B cell lines, human full length 
Quantitative real-time PCR
Total RNA was extracted from cells using Trizol (Invitrogen Corp, Carlsbad, CA) and was reversely transcribed using the reverse transcriptase cDNA synthesis kit (Fermentas, St Leon-Rot, Germany). cDNA was then used as template in the quantitative real-time PCR (qRT-PCR) (Supplementary methods).
cDNA microarray analysis
Agilent-014850 Whole Human Genome Microarrays 4x44K G4112F were used in this study. This Chip targets > 20,000 genes with >40000 probes derived from a broad survey of well known sources such as RefSeq, Goldenpath, Ensembl, Unigene and others. The resulting view of the human genome covers 41K unique genes and transcripts which have been verified and optimized by alignment to the human genome assembly and by Agilent's Empirical Validation process. Total RNA (>300 ng) was extracted from four independent cultures of PC3 GFP , PC3  HIC1 cells and C4-2B  GFP , 9 were resuspended in loading buffer and denatured at 100°C for 10min. 
Small animal PET-CT scanning
For the same purpose as above, the above mice injected PC3 HIC1Luc and PC3 GFPLuc in 2 months were underwent 18 F-FDG small-animal PET and micro-CT in Shanghai Ruijin △XI mutants were cloned into the pGL3 basic reporter gene vector to generate some CXCR7 promoter truncation constructs (Supplementary methods).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) was conducted using an EZ-ChIP kit (Millipore Upstate, New York, USA). The dissociated DNA from immunoprecipitated protein/DNA complex was used for PCR assay (Supplementary methods).
Statistical analysis
qRT-PCR and cell proliferation were analyzed using Student's t test, 2-tailed, with (Fig. 1B) . Next, the methylation status of 11 CpG sites within the CpG island 2 of HIC1 by sequencing PCR products after bisulfite treatment were further assayed ( Supplementary Fig. 1B) . The results showed that the mean methylated percentage among 11 CpG sites of HIC1 promoter was greatly higher in C4-2B and PC3 cells than PrECs (Fig. 1C) . Moreover, the levels of methylated HIC1 promoter in 36 primary Chinese PCa tissues compared with the respective healthy control cases were 80.3% ± 8.7 vs. 31.56% ± 11.3 ( Fig.1D , Supplementary Table1). Similar results were observed in 20 plasma DNAs from these patients ( Supplementary Fig.1C ). These findings demonstrate that HIC1 promoter region is hypermethylated in PCa.
Functional analysis after restoring HIC1 expression in PCa cells
Due to silencing of HIC1 expression in PCa cells by hypermethylation, we therefore restored its expression in C4-2B and PC3 cells by using lentivirus vector. Fig.2A showed that restored HIC1 expression was confirmed by Western blot assays in both 
Tumorigenicity and metastasis by HIC1 restoring expression in mice
To evaluate that HIC1 plays a role in tumor growth, we transplanted PC3 HIC1 , Fig.4B, 4C ). In brief, these findings strongly suggest that HIC1 expression had a significant effect on reducing osseous destruction by PCa cells.
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Identification of downstream genes by HIC1
To explore potential downstream targets induced by HIC1, we analyzed the PCa cells, 310 up-regulated genes and 267 down-regulated genes were commonly observed in PC3 and C4-2B cells. As shown in Fig. 4A , the picked up 36 cancer-associated genes for cluster mapping on the MeV microarray analysis platform (www.tm4.org/mev.heml). We also identified genes related to molecular function and picked up the top 36 gene sets that overlapped with different function-clusters for exhibition ( Fig. 4B and Supplementary Table 2 ).
CXCR7 expression modulated by HIC1 in PCa
Among the genes markedly regulated in two PCa cells with HIC1 expression, we paid attention to CXCR7 because our previous (21) and recent studies (22) demonstrated that CXCR7 expression is closely associated with PCa, bladder cancer, breast cancer progression. In addition, CXCR7 has been described as a direct HIC1 target gene in U2OS cells overexpressing HIC1 and the regulatory region of CXCR7 promoter contained several functional HIC1 consensus binding sites (HiRE, HIC1 responsive element) (18) . In this regard, we set out to explore the mechanisms through which CXCR7 expression is modulated by HIC1 in PCa cells. Firstly, using qRT-PCR and FACS analysis confirmed that HIC1 expression markedly inhibited CXCR7 level in PC3 and C4-2B cells (Fig.5A , 5B), consistent with the above microarray assays. Similar result was also observed in histological staining of subcutaneous tumors with HIC1 expression (Supplementary Fig. 5A ). Moreover, expression of CXCR7 mRNA and protein level was down-regulated in term of restoring expression of HIC1 mRNA and protein by 5-AZa treatment only in PCa cells (Fig. 5C, 1B and 5D ), but not in PrECs. In contrast, knockdown of HIC1 expression by siRNA1 and siRNA3 enhanced CXCR7 level in PC3 cells and PrECs (Supplementary Fig.5B ). Finally, high density tissue microarrays were stained with both an anti-human CXCR7 and HIC1. Representative images are shown in Fig. 6A , indicating that expression of CXCR7 in cancer tissues was higher than the normal and PIN tissues as reported previously (21) . In contrast, HIC1 expression was markedly elevated in the normal and PIN tissues compared with the cancer tissues. Quantitative analysis confirmed the similar observations (Fig. 6B ).
CXCR7 is a direct HIC1 target gene
Based on the above assays, these findings implied that CXCR7 may be reversibly modulated by HIC1. To determine the underlying mechanism, we utilized a series of CXCR7 truncated promoter/reporter fusion plasmids containing progressive 5' 
deletions, which allowed us to perform luciferase promoter-reporter assays. These constructs were then transfected alone or with the pcDNA3-FLAG-HIC1 expression vector into PC3, C4-2B cells and promoter activities were therefore measured in the absence or presence of HIC1. The data showed that, compared with these constructs transfection alone, transient transfection of HIC1 in PC3 cells markedly inhibited the CXCR7 promoter activity in the -813/+168, -386/+164 and -191/+164 constructs, even in the smaller construct -26/+164. The similar inhibitory effect was also shown in C4-2B cells (Fig. 6C) . These results suggest that the regulatory region primarily involved in the HIC1-mediated repression of CXCR7 is located in the -26/+164 upstream region of the promoter that contains one of the two phylogenetically conserved and adjacent HIC1 responsive element (HiRE), such as sites IX and XI, as assayed by Van Rechem et al (18) . To verify the possibility, we used the ΔXI constructs in XI HiRE site with a mutation (TGC into CAT) to abolish the ability of HIC1 binding.
In line with the previous findings (18), the -813/+168, -191/+164 and -26/+164 constructs both display a high basal activity repressed by HIC1 expression. Notably, the mutated ΔXI constructs that the most significantly decreased repression ration by HIC1 was observed in the longest promoter construct -813/+168, but not in -191/+164 and -26/+164 constructs (Fig. 6D) . These findings imply that the CXCR7 promoter is negatively regulated by HIC1.
To determine that CXCR7 is indeed a direct target gene of HIC1, we performed ChIP assays using 100kD molecular weight of HIC1 antibody (Sigma, St Louis, MO, USA) and then analyzed the pull-down DNA. The primers were designed to amplify the region mediating the repressive effects of HIC1 on the -26/+164 site of CXCR7 promoter and containing adjacent HiREs as shown in the above assays ( Supplementary   Fig. 6A ). As assay procedure control, we used primers located in the GAPDH promoter ( Supplementary Fig. 6B ). As shown in Supplementary Fig.6A , CXCR7 was markedly amplified from the HIC1-immunoprecipitated PC3 and C4-2B chromatins compared with PrEC chromatins, but not from chromatin immunoprecipitated by the control rabbit IgG. Taken together, these results demonstrate that endogenous HIC1 proteins are highly recruited onto the CXCR7 promoter in vivo both in PC3, C4-2B cells. This study aimed to further our understanding of the role that HIC1 plays in PCa progression. Our data showed that HIC1 promoter hypermethylation was presented in Chinese PCa patients, potentially responsible for its progression, which has not been previously reported to our knowledge. Indeed, our study showed that restoring HIC1 expression in PCa cells markedly inhibited proliferation, migration, and invasion and induced the apoptosis in these cells. These characteristics suggest that CXCR7 plays a role in regulating immunity, angiogenesis, stem cell trafficking, and mediating organ-specific metastases of cancer (26-30). However, the mechanism underlying CXCR7 expression modulated by immediately upstream targets still remains unsettled.
In this study, we further demonstrated that endogenous HIC1 could bind to the promoters of CXCR7, thus resulting in inhibiting its effect. Interestingly, the mutated ΔXI constructs that the most significantly decreased repression ration by HIC1 was only observed in the longest promoter construct -813/+168, but not in -26/+164 constructs.
To be fully understood, the mechanism underlying the effect of HIC1 in CXCR7 expression is warranty investigated. However, these findings imply that the CXCR7 
